We report a case in which strict anticoagulant therapy management was useful for a recurrent in-stent thrombosis after carotid artery stenting (CAS). An 84-year-old man presented with cognitive decline that progressed rapidly over two months. Head magnetic resonance imaging showed an acute-stage infarct occurring frequently in the right cerebral hemisphere, and he underwent hospitalization and treatment. On neck magnetic resonance angiography (MRA), severe stenosis was found at the origin of the right internal carotid artery. Since he took aspirin, clopidogrel, and a statin after placement of an indwelling coronary stent, we treated him by adding argatroban and edaravone drip therapy to his existing medication. CAS was performed on day 15 of the hospitalization. A small in-stent thrombosis with plaque protrusion was observed on a carotid sonogram performed at the second day after CAS, and re-examination at the seventh day confirmed enlargement of the lesion and an increase in peak systolic velocity; thus, a second CAS procedure was performed on the same day. After the second CAS, oral cilostazol was added for triple antiplatelet therapy (TAPT), but as the in-stent thrombosis increased further, we started a continuous infusion of heparin with the goal of an activated partial thromboplastin time (APTT) of 50 to 65 seconds. After starting heparin, the lesion did not progress; after 14 days of continuous heparin infusion, the patient was switched to TAPT, and regression of the plaque was confirmed. This case demonstrated to us that controlled anticoagulation therapy can be an effective treatment for cases in which a thrombus recurs within a stent after CAS.
Objective
In-stent thrombosis has been reported as a rare complication after carotid artery stenting (CAS). [1] [2] [3] [4] [5] [6] [7] It occurs only with a probability of 1% or less, but it could lead to serious outcomes. 1, 2 We report a case in which anticoagulant therapy management was useful for a recurrent in-stent thrombosis after CAS.
Case presentation
An 84-year-old right-handed man presented with cognitive decline that progressed rapidly over two months. He had a history of coronary stent placement after a previous myocardial infarction, type 2 diabetes, hypertension, and dyslipidemia. He was prescribed clopidogrel 50 mg, aspirin 100 mg, rosuvastatin 5 mg, carvedilol 2.5 mg, benidipine 2 mg, and rabeprazole sodium 10 mg (all daily doses). Other findings included a National Institutes of Health Stroke Scale (NIHSS) score of 4 points, Mini Mental State Examination (MMSE) score of 17 points, disorientation, left hemispatial neglect, and mild left paralysis. Head magnetic resonance imaging (MRI) diffusionweighted imaging (DWI) showed an acute-to-subacutephase infarction occurring frequently in the right cerebral hemisphere. On a magnetic resonance angiography (MRA) image, signals from the right intracranial internal carotid artery were reduced. On neck MRA, severe stenosis was found at the origin of the right internal carotid artery, and the plaque exhibited high intensity (a plaque/muscle ratio of 2.1) using the black blood method. A T1-weighted image suggested the presence of a vulnerable plaque ( Figure 1 ).
We diagnosed the patient with atherothrombotic brain infarction and continued oral administration of the two antiplatelet drugs that he had been taking after placement of the coronary stents. We also started argatroban and edaravone drip therapy, but transient ischemic attacks (TIAs) were occurring at a frequency of about once every two days, even after treatment was initiated. Resting cerebral blood flow on single-photon emission computed tomography (SPECT) showed a wide range of blood flow reductions in the right cerebral hemisphere.
CAS was performed on the 15th day of hospitalization because the patient experienced recurrent episodes of TIAs that were resistant to treatment with medication. We chose CAS because he was elderly and previously underwent coronary artery stent placement instead of carotid endarterectomy (CEA). We planned staged CAS because of concerns about hyperperfusion syndrome; remarkable hypoperfusion was observed on preoperative SPECT, but we could not get enough expansion with percutaneous transluminal balloon angioplasty (PTA) alone. A Precise stent (Johnson & Johnson Co., Miami, FL, USA), measuring 10 mm Â 40 mm, was placed after PTA with a 3.5-mm diameter balloon in combination with proximal and distal balloon protection devices ( Figure 2 ). Intravascular ultrasonography (IVUS) performed after stent placement showed good vascular dilation, and an in-stent thrombosis was not observed.
Postoperative SPECT at rest showed the hyperperfusion phenomenon, but the patient did not become symptomatic. On carotid color Doppler ultrasonography performed on the second day after CAS, a small low echogenic mass about 2 mm in thickness was observed in the stent. When the carotid echocardiogram was re-performed on day 7 after CAS, the lesion had increased in size and the peak systolic velocity (PSV) had increased to 180 cm/s; thus, angiography was performed on the same day. Right common carotid artery imaging showed about 50% restenosis in the stent, and a mottled contrast agent defect was recognized, which was thought to be a thrombus. We diagnosed the patient with progression of stenosis in the stent and performed stent-in-stent placement the same day. A Precise stent measuring 10 mm Â 30 mm was indwelled in combination with proximal and distal protection balloon protection devices as before and post-PTA was performed with a 4.0-mm diameter balloon (Figure 3 (a) and (b)). Although good dilation was obtained, the reconstructed IVUS image and three-dimensional rotational angiography (3DRA) revealed a slight in-stent thrombosis or plaque protrusion remaining in the proximal portion of the narrowest part of the lesion (Figure 3 (c)). We considered that it would be difficult to remove the in-stent thrombosis or plaque protrusion completely with PTA and decided to intensify the pharmaceutical treatment. We increased the oral dose of clopidogrel from 50 mg to 75 mg after reoperation and further added oral cilostazol 100 mg, and it was increased to 200 mg two days later to obtain triple antiplatelet therapy (TAPT), but the remaining in-stent thrombosis further increased (Figure 4 (a) and (b)). Therefore, we stopped oral cilostazol administration and started continuous heparin infusion therapy. Aspirin 100 mg and clopidogrel 75 mg were also continued. The patient's activated partial thromboplastin time (APTT) reference value was from 30 to 33 seconds. Daily blood sampling was conducted to strictly control the APTT in the range from 50 to 65 seconds. After the initiation of heparin therapy, the lesion did not increase in size.
Heparin administration was discontinued after 14 days (the 30th day after the initial CAS operation) and oral administration of cilostazol was resumed as TAPT ( Figure 4(c) ). PSV gradually decreased on carotid ultrasonography; color Doppler ultrasonography performed on day 34 and contrast computed tomography angiography (CTA) performed on day 37 showed apparent regression of the in-stent thrombosis (Figure 4(d) and (e)). During this treatment, the patient continued rehabilitation without any deterioration in symptoms and was discharged home when he reached a modified Rankin Scale score of 3. Cilostazol was discontinued after two months and DAPT was continued; stroke and in-stent thrombosis did not recur for six months after CAS. The time course of the treatment is shown in Figure 5 .
Discussion
There has been no definitive treatment established for in-stent thrombosis, although there are reports of strengthening antithrombotic therapy, thrombolysis, PTA, percutaneous mechanical thrombectomy, thromboaspiration, re-stenting, and stent withdrawal with CEA. 1-10 Moulakakis et al. reviewed and proposed an algorithm for management of acute carotid stent thrombosis. 3 They proposed percutaneous mechanical thrombectomy, thromboaspiration, and thrombolysis, using thrombolysis AE GP 2b/3a receptor inhibitors or surgical exploration for postprocedural stent thrombosis, and only surgical exploration for refractory thrombus. 3 Regarding the cause of in-stent thrombosis with plaque protrusion, the shape of the stent may become a problem. There is a report that post-procedural complication rates are higher in an open-cell stents group than a closed-cell stents group. 8 In this case, an open- cell stent was used in the first CAS and a closed-cell stent was considered for the second CAS. When deploying a closed stent as an inner stent, it seemed that it was necessary to increase the post-PTA balloon size and to extend it tightly in order to bring it into close contact with the first stent. Because only seven days had passed since the first CAS and hyperperfusion syndrome due to over-expansion was still a concern, an open-cell stent was also used for the second stenting.
With respect to in-stent thrombosis with plaque protrusion, it was previously reported that when all cases were evaluated by CTA within one to two weeks after CAS, in-stent low-density area was observed at a frequency of approximately 26%-43.5%. 9, 10 However, in past reports, an in-stent thrombosis increasing in size was relatively rare. 1, 9, 10 Restenosis due to in-stent thrombosis can occur after CAS, and in the case of stent removal with CEA, the plaque partially protruded inside the stent and a thrombus adhered to it. It was pathologically shown that these plaques were mainly formed by cholesterin crystals and macrophages. 1, 4 Given these reports, it is inferred that thrombus formation progresses when given the opportunity by an instent plaque protrusion, and is consistent with the course of our case. It is also similar to the process of thrombus formation in a collapsed atherosclerotic plaque. 11 In a developed plaque, many foaming macrophages accumulate and tissue factor is expressed excessively. When tissue factor is exposed to blood on the collapsed plaque, it binds to factor VII to form a tissue factor VIIa complex, coagulation cascade is initiated, and thrombin is produced. 11 Thrombin converts fibrinogen to fibrin; it not only forms a thrombus but also activates platelets to promote thrombus formation. Suppression of platelet activity by antiplatelet drugs inhibits thrombus formation, but an antiplatelet drug alone cannot directly inhibit thrombin production. 12 Although the effectiveness of GP 2b/3a receptor inhibitors on stent thrombosis has been reported, 3 it is not approved in Japan and cannot be used. It has also been demonstrated that clopidogrel resistance clearly decreased with combination clopidogrel and cilostazol therapy using the VerifyNow P2Y12 Assay (Accumetrics Inc, San Diego, CA, USA). 13 We added cilostazol in combination to enhance antiplatelet effect.
In this case, antiplatelet therapy was increased after the second CAS, but the momentum of the thrombus formation could not be stopped. However, adding anticoagulation therapy suppresses thrombin production and could have inhibited clotting activity and thrombus formation. Because sufficient days had not passed since the onset of infarction, there was concern that thrombolysis could cause hemorrhagic infarction. Decomposition of fibrin and disappearance of the thrombus after two or three weeks was probably due to the action of the physiological fibronolytic system in this patient.
In contrast, in a similar case report, a continuous heparin infusion was performed to increase the activated clotting time (ACT) to twice that at baseline with a TAPT combination for in-stent thrombosis after CAS, but in that case, the thrombus showed increased resistance to strong antithrombotic therapy and a second CAS was performed. 5 APTT accurately reflects the heparin concentration and inhibition of Xa activity. However, decisions to adjust heparin therapy based on ACT results differed from decisions based on APTT results more than one-third of the time. 14 Therefore, in the case 5 where ACT was used, there is a possibility that the ideal heparin dose adjustment was not achieved. We believe that thrombin could be suppressed safely and strongly by measuring APTT daily in the laboratory and strictly controlling it within the range of 50 to 65 seconds.
In general, switching from heparin to warfarin is considered for the continuation of anticoagulant therapy. However, in this case, considering the remarkable increase in the risk of bleeding due to the combination of double antiplatelet therapy (DAPT) and warfarin, the continuous heparin infusion was discontinued after 14 days and shifted to TAPT. Long-term persistent heparin infusion interferes with rehabilitation. Heparin was discontinued not based on a confirmation of definite regression in the in-stent thrombosis, but a judgment that the PSV decline had been maintained. The optimal timing for terminating anticoagulation therapy is unknown.
It would be helpful if there were some biomarkers to judge in-stent thrombosis, but there is no known biomarker to judge the treatment course of in-stent thrombosis. However, the PSV and high-sensitivity C-reactive protein (hs-CRP) values, which gradually decrease with the decrease in PSV, may be candidates for biomarkers. Local inflammation is strongly involved in plaque rupture and thrombus formation, and hs-CRP, which reflects plaque inflammation, is known as a biomarker of myocardial infarction and unstable plaque. 15 In recent years, reports on carotid stenosis have shown that hs-CRP values were significantly higher in patients with coexisting unstable plaque. 16, 17 Conversely, there are reports that blood hs-CRP values did not correlate with biomarkers suggesting plaque vulnerability such as the numbers of macrophages, neutrophils, and smooth muscle cells in plaque specimens collected by CEA. 18, 19 These plaques were collected at the time of planned operations, and as far as we can determine, no report examined a plaque immediately after rupture. Furthermore, the interleukin-6 (IL-6) concentration is known to increase in the local blood after an acute myocardial infarction or CAS, 20, 21 and IL-6 produced by monocytes and macrophages induces CRP production in the liver. It may be useful to consider the duration of anticoagulant therapy with reference to the hs-CRP value if hs-CRP reflects local inflammation in a freshly ruptured plaque in real time.
Even with useful articles, [1] [2] [3] [4] [5] [6] [7] 9, 10 the limitations of our report come from it being an observation of only a single case; however, the usefulness of anticoagulation treatment was clearly demonstrated in the current case.
